14 results about "Mannosamine" patented technology

This invention belongs to the field of drug carrier technology and discloses a brain-targeted nanocarrier, its preparation method, and application. The primary raw materials for preparing the brain-targeted nanocarrier include PLGA-PEG-NHS, D-mannosamine, and a sulfide donor. This brain-targeted nanocarrier utilizes the dual targeting effects of mannose and sulfide to not only target the brain but also effectively improve blood-brain barrier permeability. With its high targeting and high permeability, it can be used as a carrier to effectively deliver therapeutic drugs to the brain to exert therapeutic effects, and has promising application prospects.

The invention discloses an enzymatic cascade nanogel system targeting Lawsonia intracellularis and a preparation method of the enzymatic cascade nanogel system. The enzymatic cascade nanogel system comprises the following components: 0.05-2% of sodium alginate; 0.02 to 0.3 percent of calcium chloride; 2 to 6 percent of N, O-carboxymethyl chitosan; 0.2 to 1% of D-mannosamine hydrochloride; 0.05 to 0.2 percent of tilmicosin; 0.0005 to 0.002 percent of cerium dioxide nano enzyme; and 0.0005 to 0.002 percent of glucose oxidase. The enzymatic cascade nanogel system provided by the invention has a dual gel structure of a dynamic covalent bond core and an ionic bond shell, and can realize targeted programmed release of tilmicosin; the endocytosis of host cells on the enzymatic cascade nanogel system is actively enhanced, the intracellular transport capacity of tilmicosin is improved, and the intracellular drug concentration is improved; glucose oxidase consumes glucose to generate gluconic acid and H2O2 so as to realize'hunger therapy 'on Lawsonia intracellularis; h2O2 generated by decomposing glucose oxidase by cerium dioxide nano-enzyme generates high-concentration oxygen at an infected part, so that the living environment of the intracellular Lawsonia is deteriorated.

The present invention relates to a composition comprising sialyloligosaccharide and N-acetylmannosamine for the treatment of GNE myopathy, and a method of using same. Despite ManNac exhibiting non-significant sialylation activity in GNE knockdown (GNE KD) C2C12 skeletal muscle cells, it was confirmed that co-administration of ManNac and sialyloligosaccharide promotes sialylation more effectively than single administration, thereby exhibiting an excellent synergistic effect. Such effects have also been confirmed in an animal model of GNE myopathy, and thus the combined therapy of ManNAc and sialyloligosaccharide of the present invention is expected to be advantageously employed as a novel therapeutic approach capable of overcoming hyposialylation caused by sialic acid deficiency in GNE myopathy.

The present application relates to a method for reducing the level of high mannose type glycoprotein produced by a mammalian cell expression system and its application, the method comprising any one of the following ways or a combination of the two: (a) adding N-acetyl-D-mannosamine to the subculture medium of the previous generation of mammalian cell expression system before inoculation, then inoculating into the production medium after cultivation, and continuing cultivation; (b) adding N-acetyl-D-mannosamine to the culture medium during cultivation after inoculating the mammalian cell expression system from the subculture medium into the production medium. This method can not only effectively reduce the level of high mannose type glycosylation in the produced glycoprotein, but also does not affect the protein yield, and the cell growth and metabolism are also not affected, and other quality results such as protein purity, acid-alkali peak, etc. will not change significantly, so it is significant for the research and preparation of new antibody drugs.

Provided is a recombinant Corynebacterium glutamicum, which is genetically engineered to introduce an N-acetyl-mannosamine (ManNAc) synthetic pathway, and is genetically engineered to express a heterologous N-acetylneuraminic acid synthase, a heterologous CMP-N-acetylneuraminic acid synthase, a heterologous lactose transporter, and a heterologous sialyltransferase. Provided is a method for using the recombinant Corynebacterium glutamicum to produce sialyllactose.

The invention discloses a preparation method of an ROS response microsphere encapsulated mitochondrial targeted nootkatone loaded Mxene multifunctional composite material, and relates to the technical field of biomedicine.The preparation method comprises the steps that carboxylated Mxene nanosheets are prepared and dissolved in dimethyl sulfoxide to obtain a product MXene-COOH-NK, then the product MXene-COOH-NK is dissolved in a 2-morpholine ethanesulfonic acid MES solution to obtain a product MXene-COOH-NK-Man, and the MXene-COOH-NK-Man is loaded on the Mxene multifunctional composite material to obtain the ROS response microsphere encapsulated mitochondrial targeted nootkatone loaded Mxene multifunctional composite material. On the basis, the ROS response microsphere encapsulated mitochondrial targeted Mxene loaded nootkatone is prepared. MXene has near-infrared photothermal conversion performance and supports light controlled drug release and local mild thermal therapy, MXene-COOH at NK can directly enrich chondrocyte mitochondria after being modified by mannosamine, expression of inflammatory factors is further inhibited, boric acid ester bonds are contained in the microspheres, and the MXene-COOH at NK can be used for preparing a drug for treating chondrocyte mitochondria, so that the MXene-COOH at NK can be used for preparing a drug for treating chondrocyte mitochondria. The nootkatone is broken under the high ROS environment condition of an OA focus, fixed-point and on-demand release of the medicine nootkatone is achieved, and whole body exposure is reduced.

The application discloses a preparation method of ROS response microsphere encapsulated mitochondria targeted nocardicin loaded Mxene multifunctional composite material, relates to the technical field of biological medicine, and prepares carboxylated Mxene nanosheet, dissolves in dimethyl sulfoxide to obtain product MXene-COOH@NK, is dissolved in 2-morpholinoethanesulfonic acid MES solution to obtain product MXene-COOH@NK-Man, and on this basis, ROS response microsphere encapsulated mitochondria targeted Mxene loaded nocardicin is prepared. The ROS response microsphere encapsulated mitochondria targeted Mxene loaded nocardicin prepared by the application has the near-infrared light heat conversion performance of MXene to support light-controlled drug release and local mild thermotherapy, and after the modification of MXene-COOH@NK by mannose, the MXene-COOH@NK can be directly enriched with chondrocyte mitochondria, further inhibit the expression of inflammatory factors, the microsphere contains borate ester bonds, the borate ester bonds are broken under the high ROS environment condition of OA lesion, the site release of the drug nocardicin is realized, and the systemic exposure is reduced.

The invention provides a UDP-N-acetylmannosamine epimerase mutant as well as a recombinant strain and application of the UDP-N-acetylmannosamine epimerase mutant. Compared with a wild type, the UDP-N-acetylmannosamine epimerase mutant disclosed by the invention has higher enzyme activity, can be used for efficiently preparing N-acetylneuraminic acid, and has the potential of industrial application.

The present application provides a method for purifying N-acetyl-D-mannosamine from a microbial fermentation broth, the method comprising subjecting a fermentation broth containing N-acetyl-D-mannosamine to cation exchange chromatography and anion exchange chromatography to obtain purified N-acetyl-D-mannosamine. According to the method, the fermentation liquor containing N-acetyl-D-mannosamine is creatively purified through the ion exchange chromatography technology, so that ionic impurities and pigments are efficiently removed, the capacity of removing DNA and host residual protein is remarkably improved, and the resolution ratio and reliability of the whole process are improved.

This invention proposes a method for separating biosulfur, comprising: (1) adding an organic flocculant to a mixing tank containing a biosulfurization solution and stirring to obtain a mixed solution; wherein the organic flocculant is selected from at least one of galactosamine, N-acetylglucosamine, and mannosamine; (2) transferring the mixed solution to a settling tank and allowing it to stand to form a supernatant and a bottom precipitate; and (3) separating the supernatant and the bottom precipitate in the settling tank. The method of this invention can achieve efficient separation of biosulfur, with a biosulfur flocculation rate of 95–99 wt%. This invention also provides the application of at least one of galactosamine, N-acetylglucosamine, and mannosamine in the separation of biosulfur.

The invention relates to an antibacterial glycopeptide and application thereof in treating intervertebral space infection. The glycopeptide has a structure as shown in a formula I, in the formula I, Bip represents a 4-biphenylacetic acid fragment, FF represents a dipeptide linker of two phenylalanine, X represents a cationic antibacterial peptide fragment of 6-8 amino acids, ManN represents a mannosamine fragment, Bip and FF are connected through an amido bond, the C end of FF is connected to the N end of X, and X and ManN are connected through an amido bond. The antibacterial glycopeptides of the present application can be used for the treatment of intractable infections, especially intervertebral space infections. The invention relates to Bip-FF-X-ManNI.

The invention discloses recombinant corynebacterium glutamicum for high yield of N-acetylglucosamine, which is characterized in that corynebacterium glutamicum ATCC13032 is used as an original strain; an N-acetylglucosamine-6-phosphate deacetylase encoding gene nagA, a glucosamine-6-phosphate deaminase encoding gene nagB, a glucose-6-phosphate 1-dehydrogenase encoding gene zwf, a lactic dehydrogenase encoding gene ldhA, an N-acetylmannosamine-6-phosphate 2-epimerase encoding gene nano E, a glucosamine-6-phosphate deacetylase encoding gene nagA, a glucosamine-6-phosphate deacetylase encoding gene nagB, a glucose-6-phosphate 1-dehydrogenase encoding gene zwf, a lactic dehydrogenase encoding gene ldhA, a lactic dehydrogenase encoding gene ldhA, a an N-acetylglucosamine specific phosphotransferase encoding gene cgl2642 and a glucose transporter encoding gene ptsG are used as the specific gene of the N-acetylglucosamine specific phosphotransferase; the invention also discloses a method for preparing the recombinant glucosamine-6-phosphate acetyltransferase gene, and expresses an exogenous glucosamine-6-phosphate acetyltransferase coding gene GNA1, an exogenous glutamine-fructose-6-phosphate transaminase coding gene glmS, an exogenous glucose transporter coding gene galP and an exogenous glucose transporter coding gene glf.

The invention provides optimized upstream processes for the production of recombinant gonadotropins including corifollitropin alfa (CFA), recombinant human chorionic gonadotropin (r-hCG), and recombinant human follicle- stimulating hormone (r-hFSH) in mammalian cell culture. The processes comprise revival of CHO cells from cryopreservation, expansion in shake flasks, seed generation in wave bioreactors, and production in stirred-tank bioreactors operated in fed-batch mode. Defined media supplemented with additives such as N-acetyl mannosamine, or stabilized glutamine enhance cell viability, productivity, and glycosylation quality. Cultures are terminated at defined viability thresholds or timepoints, and clarified by sequential depth and membrane filtration. The methods offer scalability, reproducibility, and superior product quality compared to conventional approaches, enabling consistent large-scale manufacture of therapeutic gonadotropins for fertility treatments and hormone therapies.

Provided are skincare compositions comprising: a compound having retinol-like activity and an N-acetyl compound selected from the group consisting of N-aldosamines, N-acetylated amino acids and combinations thereof. Also provided are methods for treating skin comprising topically applying these compositions. Also provided are skincare compositions comprising 3-(4- farnesyloxyphenyl)-propionic acid; and a derivative of an aminosugar selected from the group consisting of N-acetyl-ribosamine, N-acetyl-arabinosamine, N-acetyl-glucosamine, N-acetyl- galactosamine and N-acetyl-mannosamine, and combinations thereof, wherein the composition is in the form of a solution, suspension, emulsion, lotion, cream, serum, gel, stick, spray, ointment, liquid wash, soap bar, shampoo, hair conditioner, paste, foam, powder, mousse, shaving cream, hydrogel, or film-forming product.